• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cassava Sciences Inc (NQ: SAVA )

    26.91 +0.77 (+2.95%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cassava Sciences Inc

    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 22
    ...
    33 34 Next >
    2 Big Stock Bets That Are Insiders Are Buying Now
    Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
    Via InvestorPlace
    CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    Quick Take Technical Analysis: Cassava Sciences, Inc
    Cassava Sciences, Inc (NASDAQ:SAVA) fell over 5% on Tuesda... 
    Via Benzinga
    While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential
    Informed investors who can handle its high risk may want to take a look at speculative biotech play SAVA stock. 
    Via InvestorPlace
    Jim Cramer Weighs In On Carnival, Canadian Pacific Railway And More
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Fulgent Genetics, Inc. (NASDAQ: 
    Via Benzinga
    Should Investors Worry About the Federal Investigation of Cassava?
    The investigation really isn't the underlying concern. 
    Via The Motley Fool
    Cassava Sciences Just Returned to the Buy Zone
    There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Intraday Session
    Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
    Via Benzinga
    Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam
    Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is... 
    Via Benzinga
    3 Biotech Stocks That Have More Than Tripled so far This Year
    But can they keep up the momentum? 
    Via The Motley Fool
    61 Biggest Movers From Yesterday
    Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    2 More Stocks Set to 2x… 5x… 10x in 2022
    Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
    Via InvestorPlace
    Topics Economy
    Exposures Interest Rates
    Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher
    Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24. The U.S.... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    See Why Cassava Sciences Shares Are Falling On Wednesday?
    The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for... 
    Via Benzinga
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Why Cassava Sciences Is Sliding Lower Today
    Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Gainers EyePoint Pharmaceuticals (NASDAQ:EYP... 
    Via Benzinga
    Today’s Hot Penny Stocks: What’s Moving ZSAN, AVGR and CEI Higher Wednesday?
    Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! 
    Via InvestorPlace
    ROKU Stock Price Predictions: How Low One Analyst Thinks Roku Will Go
    Roku (ROKU) stock price predictions aren't doing the shares any favors on Wednesday after one analyst put out a bearish take. 
    Via InvestorPlace
    Mid-Day Market Update: StoneCo Drops After Q3 Earnings; EyePoint Pharmaceuticals Shares Surge
    Midway through trading Wednesday, the Dow traded down 0.51% to 35,958.22 while the NASDAQ rose 0.03% to 15,977.88. The S&P also fell, dropping 0.13% to 4,694.96. The U.S. has... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    42 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today
    Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. 
    Via InvestorPlace
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Cassava Sciences In Hot Water Again As Shorts Claim 'Extreme' Data Manipulation
    In a filing, the short sellers claim the science backing Cassava's drug is impossible. 
    Via Investor's Business Daily
    Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ: 
    Via Benzinga
    Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
    Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy... 
    Via FinancialNewsMedia
    Exposures COVID-19
    NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc.
    San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc.. 
    Via SBWire
    Topics Lawsuit
    Exposures Financial Legal
    Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track'
    An analyst says Cassava is on track, but Cortexyme took another beating Thursday. 
    Via Investor's Business Daily
    7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
    Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. 
    Via InvestorPlace
    Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
    Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. 
    Via InvestorPlace
    Cassava Is a Sell After Accusations of Data Manipulation
    After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. 
    Via InvestorPlace
    < Previous 1 2
    ...
    14 15 16 17 18 19 20 21 22
    ...
    33 34 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.